Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world.
The company is developing a pipeline of products in child nutrition, an area dominated by multinationals such as Abbott, GSK, Kraft Heinz and Mondelez International.
In a BSE filing today, Cipla said "it has received final approval for its abbreviated new drug application (ANDA) for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration (USFDA)".
Sun Pharmaceutical Industries and Cadila Healthcare second quarter results were the major result announcements this week.
The changes are announced by Asia Index, a joint venture between S&P Dow Jones Indices LLC and BSE. The move is a part of Asia Index's semi-annual reconstitution results.
The US remains the largest market in the world and they look at it as an attractive opportunity, Umang Vohra, MD & Global CEO, Cipla.
In a BSE filing today, Cipla said "it has received final approval for its abbreviated new drug application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA)".
Centrum is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 700 in its research report dated November 07, 2017.
The company plans to either acquire a company in China or collaborate with a local partner for this.
EBITDA (earnings before interest, tax, depreciation and amortisation) grew by 18.2 percent year-on-year to Rs 804 crore and margin expanded 160 basis points to 19.7 percent in quarter ended September 2017.
Margin improvement will be closely watched as it had expanded sharply in Q1 to 18.3 percent from 16.7 percent YoY, added product mix improving and cost control.
In a BSE filing, Cipla said "its subsidiary, InvaGen Pharmaceuticals Inc. has received final approval for its abbreviated new drug application (ANDA) for Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA)".
Net Sales are expected to increase by 6.7 percent Y-o-Y (up 13.5 percent Q-o-Q) to Rs. 4001 crore, according to Kotak.
Mitessh Thakkar of mitesshthakkar.com is of the view that one can buy Sun Pharma and Escorts and can sell Indiabulls Real Estate, United Spirits and Strides Shasun.
Jewellery stocks, the likes of PC Jeweller and Titan Company which were up between 3-4 percent while ICICI Bank was the top gainer in the Nifty50 Index while SPARC plunged 11 percent intraday.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Kotak Mahindra Bank and Cipla and can sell SREI Infrastructure.
Sandeep Wagle of powermywealth.com is of the view that one can buy Cipla and sell DLF while can hold Piramal Enterprises and CRISIL.
Ashwani Gujral of ashwanigujral.com recommends buying Glenmark Pharma, Ajanta Pharma and Cipla.
Rajat Bose of rajatkbose.com is of the view that one can buy Cipla and sell Reliance Capital.
Rajat Bose of rajatkbose.com recommends buying Novartis, Cipla, Bajaj Auto and Rain Industries.
Mitessh Thakkar of miteshthacker.com suggests buying Cipla and Coal India.
In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.
Rajat Bose of rajatkbose.com suggests buying Cipla, Tata Elxsi and ACC.
Under the shareholders' agreement, if any of the parties to the pact wishes to transfer their shares in the company, they shall first offer the other parties a pre-emptive right to acquire such shares, Cipla said in a filing to the BSE.
Mitessh Thakkar of mitesshthakkar.com suggests buying Cipla, Oil India and Petronet LNG and advises selling Larsen & Toubro and Raymond.